Aubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018
|
|
- Marion Fletcher
- 6 years ago
- Views:
Transcription
1 Aubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Aubagio (teriflunomide) when it is determined to be medically necessary because the following criteria are met. When Policy Topic is covered Coverage of Aubagio is recommended in those who meet the following criteria. Food and Drug Administration (FDA)-Approved Indications 1. Relapsing Forms of Multiple Sclerosis (MS) in Patients Who Are Not Currently Receiving Aubagio. Approve for patients who meet the following criteria (A, B, and C): A) The patient has a relapsing form of MS (relapsing forms of MS include relapsing-remitting multiple sclerosis [RRMS], secondary-progressive multiple sclerosis [SPMS] with relapses, and progressive-relapsing multiple sclerosis [PRMS]); AND B) The agent is prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of MS; AND C) The patient meets ONE of the following conditions (i or ii): i. The patient is unable to administer injections due to dexterity issues or visual impairment; OR ii. The patient has tried one of the following: Avonex, Rebif, Betaseron, Extavia, Copaxone, Glatopa (glatiramer acetate injection for SC use) or Plegridy (peginterferon beta-1a for SC injection). Aubagio is indicated for the treatment of patients with relapsing forms of MS. 1 MS can be a devastating neurological disease and requires extensive follow-up and monitoring of disease activity (e.g., MRI studies to determine axonal damage). Patients are usually followed by a neurologist or a physician who specializes in the treatment of MS, or after consultation with such a specialist if access is limited, to determine the most appropriate care. The interferon beta products and Copaxone have been available in the US since the mid-1990s and have established efficacy and long-term safety. Experience with Aubagio in patients with MS is limited and long-term safety data are not available. Guidelines by the National MS Society, updated in 2008, recommend interferon beta products and Copaxone as first-line therapy as soon as possible after a definite diagnosis of MS with active, relapsing disease, or in those who have experienced a first attack who are at high risk for MS. Extensive, evidence-based, nationallyrecognized updated guidelines are not available that include Aubagio. In general, Copaxone is at least as effective as interferon beta products. 6-7 There are limitations in comparing the more recently performed pivotal trials with Aubagio with the pivotal trials involving interferon beta products and Copaxone (e.g., heterogenous patient populations, use of different MS diagnostic criteria, varying standards of care, different annualized relapse rates at baseline). Although the data are not comparative, in the TEMSO study Aubagio reduced the relapse rate by 30%, which is similar to that observed in the pivotal clinical trials with interferon beta products and Copaxone. 2,6 Also, the TENERE study suggests that Rebif is at least as effective as Aubagio. 3 The pivotal trials with Tecfidera (dimethyl fumarate capsules) and Gilenya (fingolimod capsules) suggest improved efficacy compared
2 with Aubagio. 8-9 However, indirect comparisons among pivotal trials of more recently approved oral disease-modifying agents for MS also should be interpreted cautiously for many of the previously stated reasons. 2. Relapsing Forms of Multiple Sclerosis (MS) in Patients Who Are Currently Receiving Aubagio or Who Have Received Aubagio in the Past. Approve if the patient meets the following criteria (A and B): A) Patient has a relapsing form of MS, (relapsing forms of MS are RRMS, SPMS with relapses, and PRMS); AND B) The agent is prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of MS. Aubagio is indicated for the treatment of patients with relapsing forms of MS. 1 MS can be a devastating neurological disease and requires extensive follow-up and monitoring of disease activity (e.g., MRI studies to determine axonal damage). Patients are usually followed by a neurologist or a physician who specializes in the treatment of MS, or after consultation with such a specialist if access is limited, to determine the most appropriate care. When Policy Topic is not covered Aubagio has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for noncoverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.) 1. Patient has a Non-Relapsing Form of Multiple Sclerosis (MS) [e.g., primary progressive MS]. The efficacy of Aubagio has not been established in patients with MS with non-relapsing forms of MS Concurrent use of Aubagio with Other Disease-Modifying Agents Used for Multiple Sclerosis (MS) [e.g., Avonex, Rebif, Betaseron, Extavia, Copaxone, Glatopa, Plegridy, Tysabri, Gilenya, Tecfidera and Lemtrada {almetuzumab injection for intravenous use}]. These agents are not indicated for use in combination. 1 Some preliminary data have studied Aubagio in combination with interferon beta products 10 and Copaxone in patients with relapsing forms of MS 11. The long-term safety of these combinations in the treatment of MS has not been established. 1 Larger, Phase III investigations need to be completed before combination use can be recommended. 3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available. Considerations Aubagio requires prior authorization through the Clinical Pharmacy Department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers. Description of Procedure or Service Aubagio, a pyrimidine synthesis inhibitor, is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). 1 The recommended dose of Aubagio is 7 mg once daily (QD) or 14 mg QD. Aubagio should not be used in patients with severe hepatic impairment, women who are pregnant, or in those concurrently receiving leflunomide. The most common adverse events (AEs) with Aubagio include increases in alanine aminotransferase (ALT), alopecia, diarrhea, influenza, nausea, and paresthesia. Transaminase and bilirubin levels should be obtained 6 months before initiation of
3 Aubagio. Monitor ALT levels at least monthly for 6 months after commencing Aubagio treatment. Obtain a complete blood count (CBC) within 6 months before the initiation of Aubagio therapy. Conduct further monitoring based on signs and symptoms of infection. Prior to starting Aubagio, screen patients for latent tuberculosis (TB) infection with a tuberculin skin test. Monitor blood pressure before initiating Aubagio therapy and periodically thereafter. Elimination of Aubagio can be accelerated by administration of cholestyramine or oral activated charcoal for 11 days. Aubagio is in Pregnancy Category X. Rationale Clinical Efficacy The TEMSO (TEriflunomide Multiple Sclerosis Oral) trial studied Aubagio 7 mg QD and Aubagio 14 mg QD vs. placebo in patients (n = 1,008) with relapsing forms of MS (e.g., relapsing remitting [91.4%], secondary progressive [4.6%], and progressive relapsing [4.0%]). After 108 weeks, Aubagio 7 mg QD and Aubagio 14 mg QD reduced the annualized relapse rate (ARR) compared with patients who received placebo (ARR was 0.54 for placebo vs for Aubagio [both doses]; P < for both comparisons vs. placebo). 1-2 The percent of patients remaining relapse-free at Week 108 was also statistically significantly better for patients receiving Aubagio (53.7% for Aubagio 7 mg and 56.5% for Aubagio 14 mg) compared with placebo (45.6%). The percent of patients with disability progression at Week 108 was reduced with patients given Aubagio 14 mg QD (20.2%) compared with placebo (27.3%) [P = 0.028]. Magnetic resonance imaging (MRI) findings suggested a statistically significant decrease in disease activity with Aubagio compared with placebo. 1-2 TOWER (Teriflunomide Oral in People With Relapsing Multiple Sclerosis) was a Phase III, international, randomized, double-blind, placebo-controlled trial lasting for up to 40 months in patients with relapsing remitting MS that also showed that Aubagio 7 mg QD and Aubagio 14 mg QD led to a statistically significant 22% and 36% relative risk reduction, respectively, compared with placebo in the annualized relapse rate (n = 1,165). 1,12 For patients who received Aubagio 14 mg QD, there was a significant reduction in the relative risk of disability progression at Week 108 sustained for 12 weeks compared with placebo (15.8% vs. 19.7%; P = 0.044). 1,12 TOPIC was a double-blind, randomized, placebo-controlled trial that assessed Aubagio 7 mg QD and Aubagio 14 mg QD for up to 108 weeks in patients with relapsing MS (n = 614). Patients were required to have experienced a first clinical event consistent with acute demyelination occurring within 90 days of randomization with two or more T2 lesions at least 3 mm in diameter that were suggestive of MS. 1,13 More patients in the Aubagio 7 mg QD group (70.5%) and the Aubagio 14 mg QD group (n = 72.2%) were free of relapses compared with patients in the placebo group (61.7%) [P < 0.05 for both Aubagio groups]. 1 The TENERE (TErifluNomidE and REbif ) study assessed Aubagio 7 mg QD, Aubagio 14 mg QD, and Rebif [interferon beta-1a [subcutaneous {SC}], titrated up to 44 mcg SC three times weekly (TIW), in patients mainly with relapsing-remitting MS (n = 324) for up to 48 weeks. 3 The trial was not performed in the US; therefore, a foreign formulation of Rebif was utilized. Of note, Aubagio was administered in a double-blind fashion whereas Rebif was given open-label. The primary composite endpoint was time to failure, which was defined as the first occurrence of confirmed relapse or permanent treatment discontinuation for any cause. Many secondary endpoints were assessed including the ARR, defined as the number of confirmed relapses during the treatment period per patient-year. No difference was detected between either the Aubagio or Rebif group regarding time to failure. At Week 48, the cumulative percentage of estimated failures utilizing the Kaplan-Meier Method was 37%, 36%, and 33% for Rebif, Aubagio 7 mg QD, and Aubagio 14 mg QD, respectively. Permanent treatment discontinuation rates were higher for patients receiving Rebif (24.0% [n = 25/104]) compared with Aubagio 7 mg QD (6.4% [n = 7/109]) and Aubagio 14 mg QD (13.5% [n = 15/111]). Confirmed relapse was noted in fewer patients receiving Rebif (15.4% [n = 16/104]) compared with Aubagio 7 mg QD (42.2% [n = 46/109]) and Aubagio 14 mg QD (23.4% [n = 26/111]). No difference was noted in adjusted ARR between Rebif and Aubagio 14 mg QD (0.22 vs. 0.26; P = 0.6), although ARR was significantly higher in patients receiving Aubagio 7 mg QD (0.41; P = 0.03 vs. Rebif).
4 Disease Course Four different clinical courses of MS have been described. 4 Relapsing-remitting MS is characterized by acute worsening of neurologic function, usually followed by almost complete recovery with limited progression. Approximately 85% of patients are initially diagnosed with relapsing-remitting MS. Disability progression is usually minimal. However, many patients will experience secondary progression of disability in time and will have a different form of MS. Secondary progressive MS begins as an initial relapsing-remitting course, but the disease transitions in many patients to a steadily progressive form with increased loss of function. Of the 85% of patients who started with relapsingremitting MS, more than 50% will develop secondary progressive MS within 10 years and 90% within 25 years. Primary progressive MS is noted as a continued worsening of disease from onset, without distinct relapses. Approximately 10% of patients are diagnosed with primary progressive MS. Progressive relapsing MS starts with disease progression at onset with occasional acute relapses but continued disease progression. Around 5% of patients appear to have progressive-relapsing MS at diagnosis. Around 10% of patients with MS have a benign MS course, which is generally determined retrospectively. Relapses or exacerbations of MS can vary in severity, duration, and frequency, as well as in the symptomatology. GUIDELINES Evidence-based guidelines that extensively review the clinical literature regarding therapies for MS have not been updated recently. In 2008 the National Clinical Advisory Board of the National MS Society published an expert opinion paper regarding treatment recommendations for physicians. 5 Initiation of therapy with an interferon beta medication (i.e., Avonex [interferon beta-1a, intramuscular {IM}]), Rebif, Betaseron /Extavia [interferon beta-1b SC]), or Copaxone (glatiramer acetate injection SC) should be considered as soon as possible after a definitive diagnosis of MS with active, relapsing disease, and may be considered for selected patients with a first attack who are at high risk of MS. Therapy should be continued indefinitely unless it is not tolerated or benefit is not obtained. The oral disease-modifying agents approved for relapsing forms of MS have not been incorporated into the expert opinion paper. Tysabri (natalizumab injection for intravenous [IV] use) is generally recommended for patients who have had an inadequate response to, or are unable to tolerate other MS therapies. Treatment with mitoxantrone injection may be considered for selected relapsing patients with worsening disease or patients with secondary-progressive MS with worsening, whether or not relapses are occurring. REFERENCES 1. Aubagio tablets [prescribing information]. Cambridge, MA: Genzyme Corporation (a Sanofi company); October O Connor P, Wolinsky JS, Confavreux C, et al, for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14): [Supplementary Appendix]. 3. Vermersch P, Czlonkowska A, Grimaldi LM, et al, for the TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomized, controlled phase 3 trial. Mult Scler. 2014;20(6): Clinical bulletin. Information for health professionals. Overview of multiple sclerosis by Rosalind Kalb and Nancy Reitman National Multiple Sclerosis Society. 5. Expert Opinion Paper by the Medical Advisory Board of the National Multiple Sclerosis Society. Treatment recommendations for physicians. Disease management consensus statement Available at n_disease-management-consensus-statement-(under-revision).pdf. Accessed on July 1, McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics. 2013;10(1): Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicenter, randomized, parallel, open-label trial. Lancet Neurol. 2008;7:
5 8. Tecfidera delayed-release capsules [prescribing information]. Cambridge, MA: Biogen Idec; April Gilenya [package insert]. East Hanover, NJ: Novartis; May Freedman MS, Wolinsky JS, Wamil B, et al, for the teriflunomide multiple sclerosis trial group and the MRI analysis center. Teriflunomide added to interferon-β in relapsing multiple sclerosis. A randomized phase II trial. Neurology. 2012;78: Freedman MS, Wolinsky JS, Wamil B, et al. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis [abstract p17]. Int J MS Care. 2011;13(Suppl 3):9 12. Confavreux C, O Connor P, Comi G, et al, for the TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2014;13: Miller AE, Wolinsky JS, Kappos L,e t al, for the TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10): Billing Coding/Physician Documentation Information Aubagio is a specialty pharmacy benefit Additional Policy Key Words Policy Policy Implementation/Update Information 07/2016 Policy reviewed-no changes 07/2017 Annual review-no changes to policy statement State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.
Multiple Sclerosis Agents
Multiple Sclerosis Agents Policy Number: 5.01.614 Last Review: 09/2018 Origination: 07/2014 Next Review: 09/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationLemtrada (alemtuzumab)
Lemtrada (alemtuzumab) Policy Number: 5.02.517 Last Review: 7/2018 Origination: 8/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Lemtrada
More informationClinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Aubagio) Reference Number: CP.PHAR.262 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.CPA.331 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Betaseron, Extavia) Reference Number: CP.PHAR.256 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at
More informationClinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 04.01.17 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationApproved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy. Date approved: 06/21/17
Integrated Healthcare Services and Criteria Document: Reference #: PC/B016 Page: 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA
More informationMS Injectable Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: MS Injectable Drugs Page: 1 of 5 Last Review Date: November 30, 2018 MS Injectable Drugs Description
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. Multiple Sclerosis Agents Ampyra Aubagio Avonex Betaseron Copaxone Extavia Gilenya Glatopa Plegridy Rebif Tysabri
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B016 Page: 1 of 4 and Therapeutics Quality PRODUCT APPLICATIO: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne
More informationThere are currently 4 US Food and Drug
DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)
Public slides part 1 (Redacted) Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) 3 rd Appraisal Committee meeting Committee B, 16 th November 2017 Previous Appraisal
More informationPrior Authorization Form
5/2/2017 Prior Authorization Form INTOTAL HEALTH PLAN (SPC) Multiple Sclerosis MMT SGM This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationIR Thematic Call on Multiple Sclerosis
Teresa, Multiple Sclerosis, United States IR Thematic Call on Multiple Sclerosis October 3 rd, 2013 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab),
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationSupplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values
Supplementary Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Appendix A: Cost-effectiveness Model: Additional Input Parameter Values Detailed Input Tables Table A.1: Annual Probability
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationThe MS Disease- Modifying Medications. General information
The MS Disease- Modifying Medications General information Current as of April 2013. This online brochure is updated with breaking news as required. If you have a printed a copy of this publication, please
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationS.E.A.R.C.H. SM Patient Workbook
S.E.A.R.C.H. SM Patient Workbook How to S.E.A.R.C.H. SM for the Right MS Therapy For You! What is S.E.A.R.C.H. SM? The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by
More informationSESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY
SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY Bruno C. Musch, MD PhD Baveno, Italy November 30th, 2013 DISCLOSURE OF INTEREST Dr.Musch is currently Medical Director in GENENTECH/Roche,
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0023O Effective Date: June 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationHelen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester
Helen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester helen.pervanas@mcphs.edu Objectives Describe the pathophysiology, diagnosis and prognosis of MS Discuss disease
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 COPAXONE 20 mg/ml, solution for injection, pre-filled syringe B/28 (CIP code: 363 840-1) Applicant: SANOFI-AVENTIS
More informationLEMTRADA (ALEMTUZUMAB)
LEMTRADA (ALEMTUZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0023P Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationTysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab
PHARMACOVIGILANCE AND REGISTRY PROGRAMMES Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab Eric Van Ganse Pharmacoepidemiology, CHU-Lyon France OUTLINE I. GOOD REGISTRY PRACTICE
More informationTechnology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303
Teriflunomide for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 22 January 2014 nice.org.uk/guidance/ta303 NICE 2018. All rights reserved. Subject to Notice of
More informationThe Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan
The Cost-Effectiveness of Treatment Options for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Modeling Analysis Plan October 7, 2016 Prepared for Institute for Clinical and Economic Review,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple
More informationNational Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008
Cladribine (Movectro) for multiple sclerosis; relapsing-remitting April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report October 2014 Drug Teriflunomide (Aubagio) (14 mg film-coated tablet) Indication Teriflunomide is indicated as monotherapy for the treatment of patients
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationCredit Suisse Healthcare Conference
Credit Suisse Healthcare Conference Bill Sibold Executive Vice President, Sanofi Genzyme Scottsdale, Arizona - November 8, 2017 Forward Looking Statements This presentation contains forward-looking statements
More informationDisease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value
Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Response to Public Comments on Draft Evidence Report January 26, 2017 Institute
More informationMedication Prior Authorization Form
(Orelizumab) Policy Number: 1073 Policy History Approve Date: 05/19/2017 Effective Date: 05/19/2017 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Tysabri, (natalizumab), Lemtrada (alemtuzumab), Page 1 of 21 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Tysabri (natalizumab), Lemtrada (alemtuzumab),
More informationEvidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Evidence Review Group s Report Dimethyl fumarate for treating relapsing-remitting multiple sclerosis Produced by CRD and CHE Technology Assessment Group Authors Gill Norman, Research Fellow, CRD Stephen
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.45 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationA Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis
Original Article J Clin Med Res. 2018;10(2):88-105 A Multiple Treatment Comparison of Eleven Disease- Modifying Drugs Used for Multiple Sclerosis Vida Hamidi a, Elisabeth Couto a, Tove Ringerike a, Marianne
More informationTechnology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320
Dimethyl fumarate ate for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320 NICE 2018. All rights reserved. Subject to Notice
More information2018 ECTRIMS Data Review Call. October 2018
2018 ECTRIMS Data Review Call October 2018 TG Therapeutics Michael S. Weiss, CEO Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMultiple sclerosis (MS) is a chronic, unpredictable
Prescription Utilization by Multiple Sclerosis Patients in the United States Drug Trends Anna A. Theodorou, RPh, MBA; Kelly M. Johnson, MBA; Stacey Ruf, PhD; and John A. Szychowski, AAS, BS Multiple sclerosis
More informationThe Medical Letter. on Drugs and Therapeutics. Volume 58 June 6, Drugs for Multiple Sclerosis... p 71. Important Copyright Message
The Medical Letter on Drugs and Therapeutics Volume 58 ISSUE ISSUE No. 1433 1496 Volume 56 IN THIS ISSUE Drugs for Multiple Sclerosis... p 71 Important Copyright Message FORWARDING OR COPYING IS A VIOLATION
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationExtending Our Leadership Position in Multiple Sclerosis. December 12, 2018
Extending Our Leadership Position in Multiple Sclerosis December 12, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: our strategy
More informationMAY 2018 RESEARCH U P D A T E
MAY 2018 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Tom Garry with Stephen Krieger, MD and Michelle Fabian, MD Reviewed by Jack Burks, MD Edited by Susan Courtney The 2018
More informationDrug Name (select from list of drugs shown) Tysabri (natalizumab) Quantity Frequency Strength Route of Administration
04/30/2014 Prior Authorization Form MERCY CARE PLAN (MEDICAID) Tysabri (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationMultiple Sclerosis International Federation December 2018
MSIF WHO EML APPLICATION Multiple Sclerosis Disease-Modifying Therapies 1. Summary statement of the proposal for inclusion In 2015, an application for widening the indication of azathioprine to cover multiple
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationMAY 2017 RESEARCH U P D A T E
MAY 2017 MS RESEARCH U P D A T E MS RESEARCH U P D A T E Written and compiled by Michelle Fabian, MD and Stephen Krieger, MD Includes additional material by Margaret M. McCormick, RN, BSN, MSCN Reviewed
More informationPharmacy Accreditation
Specialty Pharmacies and Care Coordination in Multiple Sclerosis Aimee M. Banks, PharmD, BCPS Specialty Pharmacist Vanderbilt University Medical Center Multiple Sclerosis Center Nashville, Tennessee Pharmacy
More informationBeta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32) [ID809]
Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly. The Appraisal Committee is interested in receiving comments on the following:
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More informationClinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Clinical Utility of Glatiramer Acetate in the Management
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationThe Latest Innovations in the Drug Pipeline for Multiple Sclerosis
CLINICAL SPECIAL FEATURE The Latest Innovations in the Drug Pipeline for Multiple Sclerosis Lea Radick and Stanton R. Mehr Am Health Drug Benefits. 2015;8(8):448-453 www.ahdbonline.com Disclosures are
More informationFrancesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, and Paolo Gallo. 1. Introduction. 2. Materials and Methods
Multiple Sclerosis International Volume 2015, Article ID 369348, 5 pages http://dx.doi.org/10.1155/2015/369348 Clinical Study Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression
More informationThe Latest Therapies for MS: Weighing Respective Benefits and Risks
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/frontlines-multiple-sclerosis/the-latest-therapies-for-ms-weighingrespective-benefits-and-risks/9639/
More informationMycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study
Received: 20.6.2010 Accepted: 5.8.2010 Original Article Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: a preliminary study Masoud
More informationEvidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal
Evidence Review Group s Report Template This template should be completed with reference to NICEs Guide to the Methods of Single Technology Appraisal Title: Fingolimod for the treatment of relapsing remitting
More informationEvidence-Based Medicine What it Is. Critical Analysis of Clinical Trials Assessing Therapeutic Value
Critical Analysis of Clinical Trials Assessing Therapeutic Value Douglas S. Goodin, M.D. Professor of Neurology, UCSF Any astronomer can predict just where every star will be at half past eleven tonight.
More informationAntibody therapy of multiple sclerosis Prof. Alastair Compston Dr. Alasdair Coles
Antibody therapy of multiple sclerosis & Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, U.K. 1 The story of multiple sclerosis: 1838-1993 2 The symptoms of
More informationRESEARCH/CLINICAL UPDATE
National Multiple Sclerosis Society 733 Third Avenue New York, New York 10017-3288 Tel +1 212.986.3240 Fax +1 212.986.7981 E-mail nat@nmss.org nationalmssociety.org October 30, 2007 RESEARCH/CLINICAL UPDATE
More informationDisclosures and Acknowledgments
214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis
More informationCladribine. Spirella Building, Letchworth, SG6 4ET reg charity no
Cladribine Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Cladribine Date of issue: February 2009 Contents Section Page 1. Introduction 1 2. How cladribine
More informationSECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
More informationDimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials
Dimethyl Fumarate and Peginterferon β-1a: New Insights Into the Pivotal Trials Pavan Bhargava, MD Johns Hopkins University School of Medicine, Baltimore, Maryland Abstract Treatment options for multiple
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationTiming is Everything: The Importance of Early Intervention in Multiple Sclerosis
Timing is Everything: The Importance of Early Intervention in Multiple Sclerosis Challenge Question: Pathophysiology Which of the following is a correct statement about the pathophysiology of MS and/or
More informationMultiple Sclerosis: KOL Insight 2016
Multiple Sclerosis: KOL Insight 2016 Multiple Sclerosis: KOL Insight 2016 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationPresentation Overview
Best Practices in the Treatment and Management of Multiple Sclerosis The Payer s Perspective Gary M. Owens, MD NAMCP April 22, 2016 1 Presentation Overview MS background and disease state review Diagnosing
More informationSyddansk Universitet DOI: /WNL Publication date: Document version Publisher's PDF, also known as Version of record
Syddansk Universitet Long-term safety and efficacy of Nine-year follow-up of the randomized TEMSO study O'Connor, Paul; Comi, Giancarlo; Freedman, Mark S; Miller, Aaron E; Kappos, Ludwig; Bouchard, Jean-Pierre;
More informationTHE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES
THE EXPANDING ARMAMENTARIUM OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES: MULTIPLE SCLEROSIS OVERVIEW II: CLINICAL ADVANCES Brief Overview Scott Newsome It is extremely important for clinicians treating
More informationGetReal - Project No
GetReal - Project No. 115546 WP1: Deliverable 1.5 (Case Study Review: Multiple Sclerosis) Lead Organisations: NICE, Novartis IMI GetReal Deliverable 1.5: Case Study on MS Disease and Treatment Overview
More informationThe last decade has witnessed the introduction of a series of disease-modifying agents as
National Multiple Sclerosis Society 733 Third Avenue New York, NY 10017-3288 Expert Opinion Paper Treatment Recommendations for Physicians Changing Therapy in Relapsing Multiple Sclerosis: Considerations
More informationUntil two decades ago, steroids were the
CMAJ Review CME Drug therapy for multiple sclerosis Eleonora Tavazzi MD, Marco Rovaris MD, Loredana La Mantia MD Until two decades ago, steroids were the only available treatment for multiple sclerosis
More informationAdvances in Immunomodulatory Therapy for Multiple Sclerosis
Advances in Immunomodulatory Therapy for Multiple Sclerosis Sona Narula, MD Children s Hospital of Philadelphia, Philadelphia, Pennsylvania Abstract Significant research has been directed toward the development
More informationCost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M
Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Bose U, Ladkani D, Burrell A, Sharief M Record Status This is a critical abstract of an economic
More informationLong-term follow up of glatiramer acetate compassionate use in Belgium
Acta neurol. belg., 2005, 105, 81-85 Long-term follow up of glatiramer acetate compassionate use in Belgium C. J. M. SINDIC 1 *, (and in order of the number of included patients) : P. SEELDRAYERS 2, L.
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationRESEARCH PAPER. Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ jnnp- 2016-314843). For numbered affiliations see end of article. Correspondence to
More informationJNNP Online First, published on December 30, 2016 as /jnnp Multiple sclerosis
Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jnnp-2016-314843). For numbered affiliations see end of article. Correspondence to Professor
More informationAs the disease progresses, patients may experience suboptimal response to their current therapy, necessitating a treatment switch.
Comments to ICER s Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Draft Evidence Report We acknowledge the difficult nature of comparing
More informationREVIEW ARTICLE. Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis. (MS) is a multifocal, demyelinating disease
Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis A Systematic Review REVIEW ARTICLE Steven L. Galetta, MD; Clyde Markowitz, MD; Andrew G. Lee, MD Background: Within the past 10
More informationFORUM IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
FORUM IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties Jagadeesh Bayry, Hans-Peter Hartung, Srini V Kaveri To cite this version: Jagadeesh Bayry, Hans-Peter Hartung, Srini V
More informationJ.P. Morgan 36 th Annual Healthcare Conference. January 10, 2018
J.P. Morgan 36 th Annual Healthcare Conference January 10, 2018 Forward Looking Statements BioCryst s presentation may contain forward looking statements, including statements regarding future results,
More information